[go: up one dir, main page]

UY27384A1 - Analogos de prostaglandina - Google Patents

Analogos de prostaglandina

Info

Publication number
UY27384A1
UY27384A1 UY27384A UY27384A UY27384A1 UY 27384 A1 UY27384 A1 UY 27384A1 UY 27384 A UY27384 A UY 27384A UY 27384 A UY27384 A UY 27384A UY 27384 A1 UY27384 A1 UY 27384A1
Authority
UY
Uruguay
Prior art keywords
sup
sub
aryl
heteroaryl
heterocyclylalkyl
Prior art date
Application number
UY27384A
Other languages
English (en)
Inventor
D Smith
K Murray
M Roepel
T Mirzadegan
T Elworthy
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27384A1 publication Critical patent/UY27384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de la fórmula I o a isómeros individuales, mezclas racémicas o no racémicas de isómeros, o a sales o solvatos farmacéuticamente aceptables de los mismos, en la que A, B, de R1 a R6 y Z tienen los significados definidos en la reivindicación 1. La invención se refiere además a composiciones farmacéuticas que contienen tales compuestos, al uso de estos compuestos como principios activos terapéuticos y a métodos de obtención de dichos compuestos.
UY27384A 2001-07-16 2002-07-15 Analogos de prostaglandina UY27384A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30572701P 2001-07-16 2001-07-16
US37134802P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
UY27384A1 true UY27384A1 (es) 2003-01-31

Family

ID=26974750

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27384A UY27384A1 (es) 2001-07-16 2002-07-15 Analogos de prostaglandina

Country Status (17)

Country Link
US (1) US6900336B2 (es)
EP (1) EP1409455B1 (es)
JP (1) JP2004521954A (es)
KR (1) KR20040015364A (es)
AT (1) ATE315022T1 (es)
AU (1) AU2002328855B2 (es)
BR (1) BR0211201A (es)
CA (1) CA2451392A1 (es)
DE (1) DE60208568T2 (es)
ES (1) ES2254726T3 (es)
MX (1) MXPA04000456A (es)
PA (1) PA8550201A1 (es)
PE (1) PE20030257A1 (es)
PL (1) PL368046A1 (es)
RU (1) RU2288913C2 (es)
UY (1) UY27384A1 (es)
WO (1) WO2003008377A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4554931B2 (ja) * 2001-12-20 2010-09-29 メルク セローノ ソシエテ アノニム プロスタグランジン調節物質としてのピロリジン誘導体
US7402605B2 (en) 2002-03-05 2008-07-22 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003077908A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7419999B2 (en) 2002-06-10 2008-09-02 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
AU2003275840A1 (en) * 2002-10-25 2004-05-13 Merck Frosst Canada Ltd 2-pyrrolidones as EP4 receptor agonists
ES2305779T3 (es) 2003-03-03 2008-11-01 Laboratoires Serono Sa Derivados de g-lactama como agonistas de prostaglandinas.
US6734206B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2004245122A1 (en) * 2003-06-06 2004-12-16 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
JPWO2005061492A1 (ja) * 2003-12-22 2007-07-12 小野薬品工業株式会社 含窒素複素環化合物およびそれらを有効成分とする薬剤
JP4893999B2 (ja) 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
US20080132543A1 (en) * 2004-10-26 2008-06-05 Wha Bin Im Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists
AU2005304764B2 (en) 2004-11-08 2012-07-12 Allergan, Inc. Substituted pyrrolidone compounds as EP4 agonists
MX2007010818A (es) 2005-03-10 2007-11-12 Allergan Inc Gamma lactamas sustituidas como agentes terapeuticos.
AU2012211448B2 (en) * 2005-03-10 2016-01-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
JP5254007B2 (ja) * 2005-05-06 2013-08-07 アラーガン インコーポレイテッド 置換β−ラクタム及び医薬におけるその使用
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
JP2010500976A (ja) * 2006-08-09 2010-01-14 アラーガン インコーポレイテッド 治療用アミド類および関連化合物
JP5566692B2 (ja) * 2007-01-31 2014-08-06 アラーガン インコーポレイテッド 治療薬としての置換ガンマラクタム類
CA2678191A1 (en) * 2007-02-15 2008-08-21 Allergan, Inc. Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure
JP5479092B2 (ja) 2007-05-08 2014-04-23 国立大学法人浜松医科大学 Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
CA2703479C (en) * 2007-10-23 2017-08-22 Allergan, Inc. 1,5-substituted gamma-lactams
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
BRPI0911347A2 (pt) * 2008-04-24 2018-03-20 Allergan Inc gama lactamas substituídas como agentes terapêuticos
WO2010006059A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
US7985765B2 (en) * 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
RU2509768C2 (ru) * 2008-09-10 2014-03-20 Асахи Гласс Компани, Лимитед Новое производное простагландина i2
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
BR112014002377A2 (pt) * 2011-08-02 2017-02-21 Ono Pharmaceutical Co agente intensificador da função diastólica do ventrículo esquerdo
AU2013292356B2 (en) 2012-07-19 2018-02-01 Cayman Chemical Company, Inc. Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
US9914725B2 (en) 2013-03-15 2018-03-13 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2014144610A1 (en) * 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CA2910398A1 (en) 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
GB201914585D0 (en) * 2019-10-09 2019-11-20 Heptares Therapeutics Ltd Prostaglandin ep4 receptor antagonist compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2556326A1 (de) 1975-12-13 1977-06-23 Hoechst Ag Neue pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
WO2000021532A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
CA2346031A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
SK8552002A3 (en) 1999-12-22 2003-09-11 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
BR0115687A (pt) * 2000-11-27 2003-09-09 Pfizer Prod Inc Agonistas seletivos do receptor ep4 no tratamento de osteoporose

Also Published As

Publication number Publication date
PA8550201A1 (es) 2003-02-14
AU2002328855B2 (en) 2005-11-24
EP1409455A1 (en) 2004-04-21
ATE315022T1 (de) 2006-02-15
DE60208568T2 (de) 2006-10-05
RU2004104625A (ru) 2005-05-27
WO2003008377A1 (en) 2003-01-30
RU2288913C2 (ru) 2006-12-10
US20030120079A1 (en) 2003-06-26
PE20030257A1 (es) 2003-03-21
BR0211201A (pt) 2004-07-13
US6900336B2 (en) 2005-05-31
JP2004521954A (ja) 2004-07-22
MXPA04000456A (es) 2004-03-18
ES2254726T3 (es) 2006-06-16
EP1409455B1 (en) 2006-01-04
DE60208568D1 (de) 2006-03-30
CA2451392A1 (en) 2003-01-30
KR20040015364A (ko) 2004-02-18
PL368046A1 (en) 2005-03-21

Similar Documents

Publication Publication Date Title
PA8550201A1 (es) Analogos de prostaglandina
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
YU96103A (sh) Novi derivati indola sa afinitetom za 5-ht6 receptor
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
YU68102A (sh) Derivati karboksilne kiseline kao ip antagonisti
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
DE60230424D1 (en) Arylsulfonyl-derivate mit 5-ht 6-rezeptor-affinität
EA200300071A1 (ru) Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
PL1660484T3 (pl) Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
SE0301371D0 (sv) New Compounds
HUP0002715A2 (hu) Benzotiofénszármazékok alkalmazása trombocitaszám csökkentésére szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141226